Answers are grounded in this paper and cite their sources.
Background/Objectives: HLA-DQA1*05 carriage has been associated with immunogenicity to anti-TNF agents in inflammatory bowel disease (IBD), but real-world data are inconsistent. We assessed whether carriage, determined by salivary genotyping, was associated with anti-TNF effectiveness, persistence and safety. Ambispective here denotes prospective ascertainment of the exposure combined with retrospective capture of outcomes. Methods: This was a single-centre ambispective cohort study of 170 adults with IBD treated with infliximab or adalimumab as their first biologic. HLA-DQA1*05 was genotyped prospectively from saliva (July 2024–April 2025); outcomes were retrieved retrospectively. Primary non-response (PNR), secondary loss of response (SLOR), treatment persistence and adverse events were compared by genotype using Kaplan–Meier and multivariable Cox analyses. Results: Of 167 patients with a conclusive genotype, 74 (44.3%) were carriers; median treatment exposure was 78.5 months. PNR occurred in 12.2% of carriers and 7.5% of non-carriers (odds ratio [OR] 1.70, 95% confidence interval [CI] 0.60–4.81), and SLOR in 53.8% and 47.7% of initial responders (OR 1.28, 95% CI 0.67–2.44). Carriage was not associated with time to SLOR (adjusted hazard ratio [HR] 1.76, 95% CI 0.97–3.21) or with all-cause discontinuation (adjusted HR 0.98, 95% CI 0.62–1.55). Conclusions: In this selected, real-world cohort with long-term follow-up, HLA-DQA1*05 carriage determined in saliva was not associated with anti-TNF failure or treatment persistence, although clinically relevant effects are not excluded. Establishing the clinical utility of HLA-DQA1*05 testing will require prospective genotyping before treatment, with systematic immunogenicity assessment.
No takes yet. Share an insight, caveat, or question.
Moreno-Torres' et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: